Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details) - Development Derivative Liability - Fair Value, Level 3 - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value at beginning of period	$ 0	$ 4,597	$ 27,726	$ 0
Non-cash research and development expense	0	3,547	4,951	5,795
Cash receipts from SFJ	0	750	750	1,500
Change in the fair value of development derivative liability	0	2,713	(33,427)	4,312
Fair value at end of period	$ 0	$ 11,607	$ 0	$ 11,607